Kyttaro Therapeutics
Company

Kyttaro Therapeutics

Biotechnology Research 4 employees
Employees
4
Contacts
1
Emails
1
Phones
1

Kyttaro Therapeutics Overview

Industry
Biotechnology Research
Employees
4
Founded
2021
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords

About Kyttaro Therapeutics

Kyttaro Therapeutics was incorporated in the US in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany. Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of mesenchymal stem cells (MSCs) for treatment of diseases with a high, unmet clinical need. Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.

Kyttaro Therapeutics Contact Details

People in AeroLeads
2
With contact data
1
Email contacts
1
50.0% coverage
Phone contacts
1
50.0% coverage

Kyttaro Therapeutics Org Chart

Sample employees and titles
Name Title Contact
Manfred Stangl Co-founder and Cso Kyttaro Therapeutics
View
Leanne Larson Senior Vice President and Managing
Email Phone

Compare Similar Companies to Kyttaro Therapeutics